Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month High – Should You Buy?

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) hit a new 52-week high during trading on Wednesday . The company traded as high as $26.16 and last traded at $25.64, with a volume of 114156 shares trading hands. The stock had previously closed at $24.56.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ADPT shares. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. BTIG Research boosted their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Piper Sandler upped their target price on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen raised their target price on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, Guggenheim boosted their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.42.

Adaptive Biotechnologies Stock Performance

The firm has a market capitalization of $4.08 billion, a price-to-earnings ratio of -62.50 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The stock’s fifty day moving average is $21.58 and its two-hundred day moving average is $17.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.17) EPS. Analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, insider Sharon Benzeno sold 154,768 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the transaction, the insider directly owned 221,278 shares of the company’s stock, valued at $4,677,816.92. This represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $18.00, for a total value of $198,000.00. Following the completion of the transaction, the insider directly owned 416,775 shares in the company, valued at approximately $7,501,950. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 1,306,971 shares of company stock worth $27,894,120. 5.70% of the stock is owned by insiders.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth $324,735,000. Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD raised its stake in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after purchasing an additional 2,216,595 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.